| name | glp1-oral-contraceptive-interaction |
| description | Counsel patients on oral hormonal contraceptive interaction with tirzepatide (Mounjaro) — requirement for non-oral contraception or added barrier method for 4 weeks after initiation and 4 weeks after each dose escalation. Use when a clinician asks "does Mounjaro affect the pill", "tirzepatide and oral contraceptive", "contraception counselling on GLP-1", or when a woman of childbearing potential is starting or escalating Mounjaro. Grounded in the Mounjaro Canadian Product Monograph (April 2026) — drug-drug interaction with combined oral contraceptives. |
Tirzepatide (Mounjaro) — Oral Contraceptive Interaction
Purpose
Tirzepatide meaningfully reduces oral contraceptive absorption via delayed gastric emptying. This requires a specific, time-limited contraception strategy — not a blanket warning. Get it wrong and an unintended pregnancy results on a drug that is contraindicated in pregnancy.
Activation
Trigger when:
- Woman of childbearing potential is starting tirzepatide.
- Patient on tirzepatide is undergoing a dose escalation.
- Contraception review in a patient on Mounjaro.
- Questions about any GLP-1 RA and the pill (note: the monograph-documented effect is for tirzepatide specifically; class effect not formally quantified but plausible).
The PK Effect (why it matters)
Single 5 mg tirzepatide dose co-administered with combined OCP (ethinyl estradiol 35 µg + norgestimate 0.25 mg):
- Cmax reduced 55–66%
- AUC reduced 16–23%
- tmax delayed 2.5–4.5 h
Mechanism: delayed gastric emptying, greatest after the first dose and after each escalation — diminishes on steady state at a given dose.
The Rule
For women using oral hormonal contraceptives on Mounjaro:
Switch to a non-oral method (IUD, implant, injection, patch, ring)
OR
Add a barrier method (condom) for:
- 4 weeks after initiation of Mounjaro, AND
- 4 weeks after EVERY dose escalation
Practical Counselling Script
"Mounjaro slows stomach emptying, which means the pill can be absorbed much less — up to about two-thirds less after a dose increase. For 4 weeks after we start the medication, and for 4 weeks after every time we step up your dose, you'll need to use a condom as well as your pill, OR switch to a method that doesn't go through the stomach — IUD, implant, injection, patch, or ring."
Dose-Escalation Timing Example
A patient starting Mounjaro 2.5 mg, escalating every 4 weeks:
| Week | Dose | Barrier/non-oral needed? |
|---|
| 0–4 | 2.5 mg (start) | YES (post-initiation window) |
| 4–8 | 5 mg | YES (post-escalation window) |
| 8–12 | 7.5 mg | YES |
| 12–16 | 10 mg | YES |
| 16–20 | 12.5 mg | YES |
| 20–24 | 15 mg (max) | YES |
| 24+ | 15 mg steady | No further escalation; risk diminished but barrier still reasonable until next visit confirms tolerance |
In practice: a patient undergoing the full 5-step escalation is covered by the rule for the entire ~6-month titration period.
Pregnancy Context
- Mounjaro is contraindicated in pregnancy.
- Long half-life (~5 days) → discontinue ≥ 1 month before planned pregnancy.
- Animal reproductive toxicity demonstrated.
- Contraceptive failure on tirzepatide is a preventable harm — this is why the rule is strict.
What This Skill Does NOT Cover
- Semaglutide (Wegovy/Ozempic/Rybelsus): monograph does not specify an OCP barrier rule. Counsel on pregnancy-avoidance generally; use clinical judgement.
- Liraglutide, dulaglutide: no specific OCP rule.
- Only tirzepatide carries the 4-week escalation barrier rule in its Canadian label.
Rules & Constraints
- Non-oral beats barrier — if feasible, switch to IUD/implant/injection/patch/ring rather than rely on condom compliance.
- Every escalation resets the 4-week clock — not just the first one.
- Document the counselling in the record.
- Rybelsus (oral semaglutide) is a different concern — 30-min dose separation for any oral co-medication; see
glp1-gi-ae-pharmacological-rescue.
- Emergency contraception: if sexual exposure during the at-risk window, offer per standard pathway; Cu-IUD is preferred on a drug that delays gastric emptying.
Reference
MOUNJARO Product Monograph, Eli Lilly Canada, 2026-04-02. §9.4 Drug-Drug Interactions (Oral Contraceptives), §7 Reproductive Health.
